HS, Arthritis, and Metabolic Burden: IL-17 Inhibitors Show Promise

A new analysis reveals that hidradenitis suppurativa (HS), a chronic inflammatory skin condition, is strongly associated with diverse patterns of arthritis and a significant metabolic burden, suggesting the need for broader screening and multidisciplinary care in affected individuals.

The findings, published in Contemporary Pediatrics and based on a review of clinical and epidemiological data, indicate that patients with HS frequently experience comorbid musculoskeletal manifestations, including axial spondyloarthritis, psoriatic arthritis, and osteoarthritis, often overlapping with metabolic syndrome components such as insulin resistance, dyslipidemia, and obesity.

Researchers note that the chronic systemic inflammation driving HS lesions—particularly involving the IL-23/IL-17 pathway—may also contribute to joint inflammation and metabolic dysregulation, creating a complex disease burden that extends beyond the skin.

“HS is increasingly recognized not just as a skin disease but as a systemic inflammatory condition with profound extracutaneous manifestations,” said one of the study’s authors. “The link between HS, inflammatory arthritis, and metabolic dysfunction underscores the importance of viewing patients through a holistic lens.”

The analysis highlights that IL-17 inhibitors, a class of biologic therapies already approved for psoriasis and psoriatic arthritis, are showing promise in treating HS, particularly in patients with moderate-to-severe disease who do not respond to conventional treatments like antibiotics or hormonal therapy.

Clinical trials and real-world evidence suggest that drugs such as secukinumab and ixekizumab can significantly reduce HS lesion counts, pain, and inflammatory markers, with some patients achieving sustained remission. These effects may be partly due to the drugs’ ability to target shared inflammatory pathways involved in both skin and joint inflammation.

Despite these encouraging results, experts caution that IL-17 inhibitors are not universally effective for all HS subtypes, and long-term safety data in this population remain limited. Screening for tuberculosis and monitoring for inflammatory bowel disease exacerbation are recommended before and during treatment, as with other biologics targeting this pathway.

Metabolic comorbidities further complicate management, as obesity and metabolic syndrome are both risk factors for HS severity and potential barriers to treatment efficacy. Weight management, lifestyle intervention, and screening for type 2 diabetes and cardiovascular risk are considered essential components of comprehensive care.

Dermatologists and rheumatologists are increasingly collaborating to manage patients with overlapping HS and arthritic conditions, recognizing that treating one domain may positively influence the other. Early referral to rheumatology is advised when joint pain, stiffness, or inflammatory back symptoms arise in HS patients.

While the exact mechanisms linking HS, arthritis, and metabolic dysfunction are still under investigation, shared genetic predispositions, dysregulation of the innate immune system, and altered gut microbiota are among the hypotheses being explored in ongoing research.

As understanding of HS as a systemic condition deepens, clinicians emphasize the need for integrated care models that address dermatological, musculoskeletal, and metabolic health simultaneously. Improved screening tools and standardized assessment protocols could help identify at-risk patients earlier and guide more personalized treatment strategies.